Ravindra Shah, MD
Ophthalmology · Portland, MENPI 1801032800
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,926 of the $4,262 with a category attached, or 68.6%. 22 manufacturers reported payments, led by Eyevance Pharmaceuticals LLC at 34.1% of the total. Reporting peaked in 2019 at $1,931 and has fallen 90.0% since, to $193 in 2025. Among ophthalmology clinicians in ME with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 79 payments — averaging $53.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eyevance Pharmaceuticals LLC$1K
- AbbVie$1K
- Alcon$497
- Sun Pharmaceutical Industries Inc.$219
- Bausch & Lomb, A Division Of Bausch Health US, LLC$137
- Glaukos Corporation$125
- plus $697 from 16 others
What the payments were for
- Consulting fees$1,25029%
- Food & beverage$2,92669%
- Education$672%
- Gifts$190%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eyevance Pharmaceuticals LLC | 7 | $1,452 |
| AbbVie(2 entities) | 15 | $1,135 |
| Alcon | 14 | $497 |
| Sun Pharmaceutical Industries Inc. | 10 | $219 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $137 |
| Glaukos Corporation | 1 | $125 |
| Rayner Intraocular Lenses Limited | 1 | $124 |
| Dompe US, Inc. | 4 | $114 |
| Genentech USA, Inc. | 4 | $80 |
| Apellis Pharmaceuticals, Inc. | 3 | $66 |
| Shire North American Group Inc | 3 | $61 |
| Oyster Point Pharma, Inc. | 2 | $53 |
| Biotissue Holdings Inc. | 2 | $36 |
| Kala Pharmaceuticals, Inc. | 1 | $24 |
| Ocular Therapeutix, Inc. | 1 | $22 |
| Novartis | 1 | $19 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Tarsus Pharmaceuticals, Inc. | 1 | $18 |
| Omeros Corporation | 1 | $17 |
| Sight Sciences, Inc. | 1 | $15 |
| Regeneron Healthcare Solutions, Inc. | 1 | $15 |
| Eyepoint US, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Flarex$1,250
- LUMIGAN$374
- VUITY$242
- DURYSTA$232
- RESTASIS$231
- Hydrus Microstent$137
- Clareon$137
- Tobradex ST$125
- KXL System$125
- Photrexa$125
- XEN GLAUCOMA TREATMENT SYSTEM$125
- OMIDRIA$124
How this compares
$4,262 in reported general payments places this provider in the 90th percentile of 74 ophthalmology providers in Maine.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 12 | $427,028 |
| RestasisCyclosporine | 78 | $110,936 |
| Cyclosporine | 79 | $51,778 |
| LumiganBimatoprost | 38 | $20,216 |
| Prednisolone Acetate | 395 | $11,632 |
| ValacyclovirValacyclovir Hcl | 141 | $10,997 |
| CombiganBrimonidine Tartrate/Timolol | 23 | $7,533 |
| ProlensaBromfenac Sodium | 19 | $6,500 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 47 | $5,953 |
| Bromfenac Sodium | 50 | $5,937 |
| MoxifloxacinMoxifloxacin Hcl | 199 | $3,250 |
| Fluorometholone | 17 | $2,079 |
| Difluprednate | 19 | $1,672 |
| ErythromycinErythromycin Base | 134 | $1,391 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 70 | $855 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $114 | $427,02812 claims |
| AbbVieRestasis, Lumigan, Combigan | $1,135 | $138,686139 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $137 | $6,50019 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 74 ophthalmology providers in Maine.
Other ophthalmology in Portland
- Charles ZacksPortland$36K
- Hallie HahnPortland$5K
- Samuel SolishPortland$4K
- Richard FrancePortland$4K
- Tamzid RahmanPortland$3K
- Margaret PollardPortland$1K
- Jackie NguyenPortland$1K
- Adam SisePortland$1K
- John LippincottPortland$994
- Benjamin FowlerPortland$763
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.